低剂量来那度胺对比安慰剂治疗非输血依赖的低危del(5q)骨髓增生异常综合征(SintraREV):一项随机双盲3期试验
SintraREV研究在西班牙、法国和德国22个大学医院开展,将61例非输血依赖的低危或中危-1 del(5q)骨髓增生异常综合征患者按2:1随机分配至来那度胺5 mg每日(28天周期,共2年)组或安慰剂组。来那度胺组至输血依赖中位时间未达到,安慰剂组为11.6个月(p=0.0027),来那度胺使输血依赖风险降低69.8%(HR 0.302,95%CI 0.132-0.692;p=0.0046)。
要点
- 来那度胺组至输血依赖中位时间未达到,安慰剂组为11.6个月(p=0.0027)。
- 来那度胺使输血依赖风险降低69.8%(HR 0.302,95%CI 0.132-0.692;p=0.0046)。
- 最常见治疗相关不良事件为中性粒细胞减少,来那度胺组24/38例(63%),安慰剂组4/21例(19%)。
核心结论
- 早期使用低剂量来那度胺持续两年可延迟非输血依赖的低危del(5q)骨髓增生异常综合征患者的输血依赖时间,并改善缓解率与缓解质量,安全性可控。
研究设计与样本
- 随机双盲3期试验,在西班牙、法国和德国的22个大学医院开展。
- 纳入年龄≥18岁、根据IPSS诊断为低危或中危-1 del(5q)骨髓增生异常综合征伴非输血依赖性贫血、未用过促红细胞生成素刺激剂、ECOG体能状态评分≤2的患者。
- 患者按2:1随机分配至来那度胺5 mg每日(28天周期)组或安慰剂组,治疗2年。
- 主要终点为基于盲态独立中心评估的至输血依赖时间,按意向治疗(ITT)和可评估人群分析;安全性分析纳入所有至少接受一剂治疗的患者。
- 2010年2月15日至2018年2月21日共随机分配61例患者:来那度胺组40例(其中2例未接受治疗),安慰剂组21例。
主要发现
- 主要终点:来那度胺组至输血依赖中位时间未达到(95%CI不适用),安慰剂组为11.6个月(95%CI 0.00-30.11),p=0.0027。
- 来那度胺使输血依赖风险降低69.8%(HR 0.302,95%CI 0.132-0.692;p=0.0046)。
- 最常见治疗相关不良事件为中性粒细胞减少:来那度胺组38例中24例(63%)发生(3级17例[45%],4级1例[3%]),安慰剂组21例中4例(19%)发生(3级1例[5%])。
- 来那度胺组38例中7例(18%)发生血小板减少(3级2例[5%])。
- 非血液学毒性中来那度胺组最常见为皮肤疾病(皮疹9/38例[23%]),其中3级1/38例(3%)。
关键数值与推荐
- 来那度胺组至输血依赖中位时间未达到(95%CI不适用)vs 安慰剂组11.6个月(95%CI 0.00-30.11),p=0.0027。
- 来那度胺组输血依赖风险HR 0.302(95%CI 0.132-0.692;p=0.0046),即风险降低69.8%。
- 中性粒细胞减少发生率:来那度胺组24/38例(63%)vs 安慰剂组4/21例(19%);来那度胺组3级17例(45%)、4级1例(3%),安慰剂组3级1例(5%)。
- 血小板减少发生率:来那度胺组7/38例(18%),3级2例(5%)。
- 皮疹发生率:来那度胺组9/38例(23%),3级1/38例(3%)。
临床怎么用
- 对于非输血依赖的低危del(5q)骨髓增生异常综合征患者,早期使用低剂量来那度胺5 mg每日持续2年可延迟输血依赖并改善缓解率与缓解质量,安全性可控。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Lenalidomide is the standard of care for patients who are transfusion dependent with chromosome 5q deletion (del[5q]) myelodysplastic syndromes. In the SintraREV trial, we aimed to investigate whether an early intervention of low lenalidomide doses for 2 years could delay transfusion dependency in patients with anaemia who were not transfusion dependent. METHODS: This randomised, double-blind, phase 3 trial, was conducted at 22 sites (University Hospitals) in Spain, France, and Germany. Eligible patients were aged 18 years or older diagnosed with low-risk or intermediate-1-risk del(5q) myelodysplastic syndromes with non-transfusion-dependent anaemia (according to the IPSS), were erythropoietin-stimulating agents naive, and had an ECOG performance status of 2 or less. Patients were randomly assigned (2:1) by means of a telephone system to receive lenalidomide 5 mg daily in 28-day cycles versus placebo for 2 years. The primary endpoint was time to transfusion dependency based on blinded independent central review. Analysis were by intent-to-treat (ITT) and evaluable population. Safety analyses included all participants who received at least one dose of treatment. This trial is registered with ClinicalTrials.gov (NCT01243476) and EudraCT (2009-013619-36) and is complete. FINDINGS: Between Feb 15, 2010, and Feb 21, 2018, 61 patients were randomly assigned to receive lenalidomide (n=40; two did not receive treatment) or placebo (n=21). The median age was 72·2 (IQR 65·4-81·9) years, 50 (82%) patients were female, and 11 (18%) were male. The median follow-up time was 60·6 (IQR 32·1-73·9) months. Regarding primary endpoint, median time to transfusion dependency was not reached (95% CI not applicable) in the lenalidomide group versus 11·6 months (95% CI 0·00-30·11) in the placebo group (p=0·0027). Lenalidomide significantly reduced the risk of transfusion dependency by 69·8% (hazard ratio 0·302, 95% CI 0·132-0·692; p=0·0046). The most frequent treatment-related adverse event was neutropenia, occurring in 24 (63%) of 38 patients in the lenalidomide group (grade 3 and 4 in 17 [45%] patients and one [3%], respectively) and in four (19%) of 21 patients in the placebo group (grade 3 in one [5%] patient). Thrombocytopenia was detected in seven (18%) of 38 patients receiving lenalidomide (grade 3 in two [5%] patients). Regarding the non-haematological toxicity, skin disorders (rash nine [23%] of 38 patients) were the most frequently described toxicities among patients receiving lenalidomide, being grade 3 in one (3%) of 38 patients. 19 serious adverse events were reported in 13 patients, 18 in the lenalidomide group and one in the placebo group, five of which were potentially related to the study drug. No treatment-related deaths were identified. INTERPRETATION: An early approach with low doses of lenalidomide across two years delays the time to transfusion dependency and improves the rate and quality of the responses, with a manageable safety profile in patients who are non-transfusion dependent with del(5q) low-risk myelodysplastic syndromes. FUNDING: Bristol Myers Squibb.
引用
- Díez-Campelo M, López-Cadenas F, Xicoy B, et al. Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial. Lancet Haematol. 2024. PMID: 39033767. doi:10.1016/S2352-3026(24)00142-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。